Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Catalent Announces Expansion of Optimelt™ HME Capabilities

Published: Thursday, October 03, 2013
Last Updated: Thursday, October 03, 2013
Bookmark and Share
Expansion of OptiMelt technology to improve bioavailability.

Catalent Pharma Solutions has announced several advancements and expansion of its OptiMelt™ Hot Melt Extrusion (HME) capabilities in Somerset, NJ.

Catalent’s OptiMelt technology is designed to help innovators overcome bioavailability challenges and create optimal delivery profiles and better dose forms.

The company has announced that results from over 10 feasibility studies for customers utilizing OptiMelt technology have demonstrated its bioavailability enhancing capabilities.

These programs were conducted across various therapeutic areas and stages of development, with several advancing to further development scale, which will ultimately result in better treatments for patients given eventual regulatory product approvals.

To create an end-to-end capability, Catalent has announced the addition of a commercial scale extruder at its Somerset facility, supplementing the development scale equipment already on site.

This added investment will allow Catalent to continue to meet high customer demand for OptiMelt while also expanding its offerings to include lab, development, and commercial scale hot melt extrusion co-located with extensive final dose form technologies across its Somerset and Schorndorf, Germany facilities.

Commenting on the development milestone and capacity expansion, Barry Littlejohns, President of Catalent’s new Advanced Delivery Technologies business, said “Our OptiMelt HME platform has continued to strengthen in the last year as development partners have recognized the benefits of our technologies. Our added commercial HME capacity will support customers’ projects as they transition to later phase clinical development and commercial supply, and also new customers desiring commercial scale direct tech transfers to our Somerset facility.”

Catalent’s integrated OptiMelt platform combines development and scale-up of HME technology with leading expertise in oral controlled release formulation and final dose form development including tablets, capsules and granules, offering customers an integrated solution to the formulation and commercialization of poorly soluble drugs.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Catalent Invests $4.6M To Further Expand Asia–Pacific Clinical Trials
Company provide of advanced delivery technologies and development solutions for drugs, biologics, consumer health products and global clinical supply services.
Friday, February 05, 2016
Catalent Announces Appointment of Sally Langa
Appointment of Ms. Langa as new Vice President of Development and Analytical Services.
Friday, January 29, 2016
Catalent to Open New Clinical Supply Facility in Japan
Construction is expected to be validated and operational in the second quarter of 2016.
Thursday, January 21, 2016
Catalent Announces Research Collaboration with Roche
Collaboration focuses on development of novel molecules using SMARTag technology to couple different therapeutic modalities.
Thursday, January 14, 2016
Catalent, Roche Collaborate On SMARTag™
Collaboration focuses on development of novel molecules using SMARTag technology to couple different therapeutic modalities.
Thursday, January 14, 2016
Catalent Biologics Announces the Appointment of Kevin Hambly
Company appoints Mr. Hambly to the position of Vice President, Business Development and Licensing.
Tuesday, December 15, 2015
Catalent Biologics Expands Capabilities
Company announces multi-site expansion of its analytical and process development capabilities.
Thursday, November 26, 2015
Catalent Biologics Adds New Technology Platform
Company has signed an exclusive licensing agreement with Excelimmune to access ACT platform.
Thursday, July 09, 2015
Catalent Awarded Grant as Part of Vaccine Research Consortium
Goal of the consortium is to develop a scalable manufacturing process for vaccines that are stable and temperature independent.
Friday, April 24, 2015
Catalent & Sanofi to Collaborate
Collaboration on SMARTag™ antibody-drug conjugate technology with Sanofi’s proprietary antibodies.
Thursday, January 22, 2015
Catalent and SELLAS Sign Exclusive Agreement
Agreement for therapeutic reprofiling of zolpidem.
Friday, December 12, 2014
Catalent and Valerion Therapeutics Collaborate
Collaboration to bring new treatments for orphan genetic disorders to market.
Thursday, December 04, 2014
Catalent Acquires Micron Technologies
Company adds global particle size technology leader to Industry’s broadest bioavailability and delivery technology offerings.
Friday, November 21, 2014
Catalent Expands Highly Potent and Cytotoxic Clinical Packaging Capabilities
Completion is expected in January 2015.
Friday, November 07, 2014
Catalent Expands its Technology Offerings in Biologics
Company acquires Redwood Bioscience and the SMARTag™ technology platform.
Friday, October 10, 2014
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Apricot Kernels Pose Risk of Cyanide Poisoning
Eating more than three small raw apricot kernels, or less than half of one large kernel, in a serving can exceed safe levels. Toddlers consuming even one small apricot kernel risk being over the safe level.
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
A lncRNA Regulates Repair of DNA Breaks in Breast Cancer Cells
Findings give "new insight" into biology of tough-to-treat breast cancer.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!